Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [911]

Predictive and prognostic biomarkers for immunotherapy in lung cancer

Dr Ignacio Gil Bazo - Fundación Instituto Valenciano de Oncología (FIVO)...

Predictive and prognostic biomarkers for immunotherapy in lung cancer ( Dr Ignacio Gil Bazo - Fundación Instituto Valenciano de Oncología (FIVO), Valencia, Spain )

Molecular oncology and translational medicine

Dr Gregg Fields - Florida Atlantic University, Florida, USA

Molecular oncology and translational medicine ( Dr Gregg Fields - Florida Atlantic University, Florida, USA )

Adjuvant nivolumab vs placebo in resected oesophageal or gastroesophageal...

Dr Ronan Kelly - Baylor University Medical Center, Texas, USA

Adjuvant nivolumab vs placebo in resected oesophageal or gastroesophageal junction cancer following chemo: Biomarker analysis ( Dr Ronan Kelly - Baylor University Medical Center, Texas, USA )

Lenvatinib plus pembrolizumab versus standard of care for previously treated...

Dr Akihito Kawazoe - National Cancer Center Hospital East, Kashiwa, Japan

Lenvatinib plus pembrolizumab versus standard of care for previously treated metastatic colorectal cancer ( Dr Akihito Kawazoe - National Cancer Center Hospital East, Kashiwa, Japan )

FOLFOX with selective use of 5FUCRT is non-inferior to 5FUCRT for treatment of...

Dr Martin Weiser - Memorial Sloan Kettering Cancer Center, New York City, USA

FOLFOX with selective use of 5FUCRT is non-inferior to 5FUCRT for treatment of LARC prior to low anterior resection with TME ( Dr Martin Weiser - Memorial Sloan Kettering Cancer Center, New York City, USA )

Efficacy and safety of belantamab mafodotin vs pomalidomide plus dexamethasone...

Prof Meletios Dimopoulos - National and Kapodistrian University of Athens...

$Efficacy and safety of belantamab mafodotin vs pomalidomide plus dexamethasone in relapsed/refractory multiple myeloma ( Prof Meletios Dimopoulos - National and Kapodistrian University of Athens, Athens, Greece )$

Triplets for newly diagnosed unfit AML patients could be feasible with...

Dr Juan Miguel Bergua Burgues - Hospital San Pedro de Alcántara, Cáceres, Spain

Triplets for newly diagnosed unfit AML patients could be feasible with substantial venetoclax reduction ( Dr Juan Miguel Bergua Burgues - Hospital San Pedro de Alcántara, Cáceres, Spain )

ASCO 2023: Highlights and analysis

Assoc Prof Bishal Gyawali - Queen's University, Kingston, Canada

ASCO 2023: Highlights and analysis ( Assoc Prof Bishal Gyawali - Queen's University, Kingston, Canada )

Axi-cel improves survival in early r/r large B-cell lymphoma

Dr Jason Westin - The University of Texas MD Anderson Cancer Center, Houston...

Axi-cel improves survival in early r/r large B-cell lymphoma ( Dr Jason Westin - The University of Texas MD Anderson Cancer Center, Houston, USA )

HCC: Improvement in RFS for atezolizumab plus bevacizumab vs active...

Prof Masatoshi Kudo - Kindai University, Higashiōsaka, Japan

HCC: Improvement in RFS for atezolizumab plus bevacizumab vs active surveillance without compromising QoL ( Prof Masatoshi Kudo - Kindai University, Higashiōsaka, Japan )

Nine-weeks trastuzumab still effective compared with one year trastuzumab for...

Prof Pierfranco Conte - Istituto Oncologico Veneto, Padova, Italy

Nine-weeks trastuzumab still effective compared with one year trastuzumab for early-stage HER2 positive breast cancer ( Prof Pierfranco Conte - Istituto Oncologico Veneto, Padova, Italy )

ATTRACTION-5: Nivolumab plus chemotherapy as postoperative adjuvant treatment...

Dr Masanori Terashima - Shizuoka Cancer Center, Nagaizumi, Japan

ATTRACTION-5: Nivolumab plus chemotherapy as postoperative adjuvant treatment for pStage III G/GEJ cancer ( Dr Masanori Terashima - Shizuoka Cancer Center, Nagaizumi, Japan )

More from ecancer